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13 Abstract
14 Purpose: Uterine sarcomas are rare and heterogeneous tumors
15 characterized by an aggressive clinical behavior. Their high rates of
16 recurrence and mortality point to the urgent need for novel
17 targeted therapies and alternative treatment strategies. However,
18 nomolecular prognostic or predictive biomarkers are available so
19 far to guide choice and modality of treatment.
20 Experimental Design: We investigated the expression of several
21 druggable targets (phospho-S6S240 ribosomal protein, PTEN,
22 PDGFR-a, ERBB2, and EGFR) in a large cohort of human uterine
23 sarcoma samples (288), including leiomyosarcomas, low-grade and
24 high-grade endometrial stromal sarcomas, undifferentiated uterine
25 sarcomas, and adenosarcomas, together with 15 smooth muscle
26 tumors of uncertain malignant potential (STUMP), 52 benign
27 uterine stromal tumors, and41normal uterine tissues. Thepotential
28 therapeutic value of the most promising target, p-S6S240, was tested
29 in patient-derived xenograft (PDX) leiomyosarcoma models.
31Results: In uterine sarcomas and STUMPs, S6S240 phos-
32phorylation (reﬂecting mTOR pathway activation) was asso-
33ciated with higher grade (P ¼ 0.001) and recurrence (P ¼
340.019), as shown by logistic regression. In addition, p-S6S240
35correlated with shorter progression-free survival (P ¼ 0.034).
36Treatment with a dual PI3K/mTOR inhibitor signiﬁcantly
37reduced tumor growth in 4 of 5 leiomyosarcoma PDX models
38(with tumor shrinkage in two models). Remarkably, the four
39responding models showed basal p-S6S240 expression, where-
40as the nonresponding model was scored as negative, suggest-
41ing a role for p-S6S240 in response prediction to PI3K/mTOR
42inhibition.
43Conclusions:Dual PI3K/mTOR inhibition represents an effec-
44tive therapeutic strategy in uterine leiomyosarcoma, and p-S6S240
45expression is a potential predictive biomarker for response to
46treatment. Clin Cancer Res; 23(5); 1–15. 2016 AACR.
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50 Introduction
51 UterineQ7 sarcoma is the general term referring to aheterogeneous
52 group of rare neoplasms with diverse histologic features, that
53 together account for 3,4% of all uterine corpus malignancies (1).
54 Although rare, they entail substantial morbidity and mortality,
55 with frequent recurrences and distant metastases, even after
56 hysterectomy (2). Leiomyosarcoma is the most frequently diag-
57 nosed and a very aggressive subtype, accounting for 60% of all
58 uterine sarcomas (1). Low-grade endometrial stromal sarcomas
59 (LGESS) account for 20% of uterine sarcomas, and they usually
60 follow a less aggressive disease course compared with leiomyo-
61 sarcoma, with a more indolent growth and delayed recurrences
62 (2). The remaining 20% of uterine sarcomas comprise high-grade
63 ESS (HGESS), undifferentiated uterine sarcoma (UUS), and ade-
64 nosarcomas. Smooth muscle tumors of uncertain malignant
65 potential (STUMP) also arise from the myometrium, and repre-
66 sent a very rare entity that cannot be diagnosed as benign or
67 malignant (3). Uterine sarcoma subtypes with HG histology are
68 generally the most aggressive and are associated with poor prog-
69 nosis. Adjuvant treatment is decided on the basis of the histologic
70 subtype, but in general is scarce and of limited beneﬁt, under-
71 lining the urgent need for new treatment options (2, 4).
72 During the past decade, our knowledge on the molecular
73 aspects of sarcomas has expanded thanks to the advent of next-
74 generation sequencing methods, which allowed biomarker
75 identiﬁcation and categorization into molecular and prognostic
76 subgroups (5, 6). However, although efforts have been taken
77 to identify therapeutic targets in sarcomas of the uterus, little
79consensus has been attained so far on their expression prevalence,
80mainly because of the limited sized sample sets available, varia-
81tions in detection protocols, and different cutoffs for positivity. In
82this study, we present the results of an immunohistochemical
83screening of relevant targets performed on one of the largest
84human uterine sarcoma sample sets published so far. Through
85collaboration within the European Network of Individualized
86Treatment in Endometrial Cancer (ENITEC), we collected more
87than 300 human uterine sarcoma samples and corresponding
88clinical data, being able to perform disease course analysis and
89investigate correlations between potential targets and clinical
90parameters. For targets analysis, we selected phosphorylated S6
91ribosomal protein (p-S6S240), the tumor suppressor and PI3K
92pathway inhibitor PTEN, platelet-derived growth factor receptor-a
93(PDGFR-a), erb-b2 receptor tyrosine kinase 2 (ERBB2/HER-2),
94and EGFR. Phosphorylated S6 is an important downstreamplayer
95in the mTOR pathway, and PTEN inhibits the PI3K pathway
96upstream. PI3K/mTOR signaling has been implicated in leiomyo-
97sarcoma, conﬁrmed by in vitro and in vivo studies (7, 8). PDGFR,
98ERBB2, and EGFR all have proven to be valuable targets in other
99cancer types. PDGFR, for example, is blocked by imatinib in
100gastrointestinal stromal tumors and dermatoﬁbrosarcoma pro-
101tuberans (9),whereas ERBB2overexpression is tackled by the anti-
102ERBB2 antibodies trastuzumab and pertuzumab in breast cancer
103(10). Finally, EGFR is targeted by antibodies such as panitumu-
104mab in head and neck and colon cancer, and by tyrosine kinase
105inhibitors geﬁtinib and erlotinib in non–small cell lung cancer
106(11). To validate the results of such screening, we preclinically
107tested themost promising target in an in vivo context, using uterine
108sarcoma patient-derived xenograft (PDX) models. Of note, being
109established by implanting freshly isolated tumor fragments into
110immunocompromised mice, PDXs have proven high histologic
111andmolecular similarity to the original tumor (12), together with
112high predictive value in terms of response to therapy (13).
113Materials and Methods
114Patient samples
115After obtaining approval from the Medical Ethics Committee
116UZ/KU Leuven and Ethics Boards in collaborating centers, 303
117archived formalin-ﬁxed, parafﬁn-embedded sarcoma samples (6
118of which are recurrences of included primary tumors), 52 benign
119uterine tumors, and 41 normal tissues were collected from 19
120European hospitals, 13 of which are associated to ENITEC. A total
121of 307unique tumor samples (malignant andbenign), alongwith
122clinical data, were collected through ENITEC, with the following
123collaborating centers: UZ Leuven, Belgium (n¼ 100), Vall d'Heb-
124ron University Hospital, Barcelona, Spain (n ¼ 37), MUMC
125Maastricht, Maastricht, the Netherlands (n ¼ 35), Charles Uni-
126versity in Prague—1st Faculty of Medicine, Prague, Czech Repub-
127lic (n ¼ 23), Turku University Hospital, Turku, Finland (n ¼ 23),
128University Hospital Graz, Graz, Austria (n ¼ 23), Haukeland
129University Hospital, Bergen, Norway (n ¼ 22), Provincial
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132 Hospitals in Gdynia - Oncology Center, Gdynia, Poland (n¼ 11),
133 Radboud UMC, Nijmegen, the Netherlands (n ¼ 7), University
134 Hospital Bonn, Bonn, Germany (n ¼ 7), UMC Utrecht, Utrecht,
135 the Netherlands (n ¼ 7), University Hospitals K€oln, K€oln, Ger-
136 many (n ¼ 6), and Karolinska University Hospitals, Stockholm,
137 Sweden (n ¼ 6). Remaining tumor samples were contributed by
138 MST Enschede (Enschede, the Netherlands), ZGT Almelo and
139 Hengelo and SKBWinterswijk, the Netherlands (n¼ 26), St. Jean,
140 Ste. Anna-St. Remi and St. Etienne, Brussels, Belgium (n ¼ 11),
141 Yperman, Ieper, Belgium (n¼ 2), AZ Turnhout, Belgium (n¼ 1),
142 Mariaziekenhuis, Overpelt, Belgium (n ¼ 1), and Imelda Hospi-
143 tal, Bonheiden, Belgium (n ¼ 1). The sample set included 157
144 leiomyosarcomas (4 recurrent matching to primary leiomyosar-
145 coma), 68 LGESSs, 26 UUSs, 15 HGESSs (2 recurrent matching to
146 primary LGESS), 17 adenosarcomas, 15 STUMPs, 5 HG uterine
147 sarcomas, not otherwise speciﬁed (HG uSAR NOS), 44 leiomyo-
148 mas, 8 endometrial stromal nodules (ESN), 23 healthy myome-
149 trial specimens, and 18 healthy endometrial samples. Of all
150 collected tissue blocks, 6,5% was obtained from surgeries before
151 2000, 62,5% was obtained between 2000 and 2010, and 31%
152 dated from 2010 or later. Patient follow-up ranged from 1month
153 to 30 years. In addition to the external classiﬁcation of tumors,
154 carried out in the center of origin by the local pathologist, all cases
155 were reviewed and reclassiﬁed in a blinded manner by the
156 dedicated central pathologist P. Moerman, uterine tumors expert,
157 according to the WHO 2014 classiﬁcation (14). Cases with
158 discordant diagnoses were excluded, and only cases where con-
159 cordance was reached by the two independent pathologists were
160 included for the screening. For clinical data collection, the Inter-
161 national Federation of Gynecologic Oncology 2009 system was
162 applied for staging of all samples (see Supplementary Table S1 for
163 clinical data and treatment modalities). HG cases were the fol-
164 lowing: all leiomyosarcoma, HGESS and UUS, HG uSAR NOS,
165 and adenosarcoma with sarcomatous overgrowth. LG cases were
166 all LGESS and LG adenosarcoma.
167 Immunohistochemical stainings
168 Parafﬁn slides (4 mm) were heated for 3 to 4 hours at 55C,
169 deparafﬁnized in toluol, and rinsed in ethanol. Tissues were
170 blocked for endogenous peroxidases by 30-minute incubation
171 in 0.5% H2O2 (107209, Merck Millipore) in methanol. After
172 washing in TBS, epitopes were retrieved as displayed in Supple-
173 mentary Table S2, which summarizes details of the IHCmethods.
174 Tissues were cooled down slowly in TBS, except after enzymatic
175 retrieval of EGFR, which was stopped by 5-minute incubation in
176 cold (4C) TBS. Upon extensive washing, tissues were blocked
177 with 1%milk powder, 2%BSA (A4503, Sigma-Aldrich), and0.1%
178 Tween-80 (822187, Merck Millipore) in TBS before antibody
179 incubation. Blocking solutions were removed and tissues were
180 incubated with antibody solutions in TBS (Supplementary Table
181 S2). The following primary antibodies were used: anti-phospho-
182 S6S240 (M7300, Dako), anti-PTEN (clone 6H2.1, M3627, Dako),
183 anti-PDGFR-a (C-20, sc-338, Santa Cruz Biotechnology), anti-
184 ERBB2 (A0485, Dako), and anti-EGFR (clone 31G7, 280005,
185 Zymed). Tissues were washed, blocked for 15 minutes (except
186 for PTEN staining), and incubated with secondary antibodies or,
187 for PTEN, with EnVision-HRP (K4001, Dako). After washing,
188 slides for EGFR and phospho-S6S240 stainings were incubated
189 with streptavidin–HRP (P0397, Dako) for 30 minutes and
190 washed again. All antibodies were visualized by 10-minute incu-
191 bation in 3,30-diaminobenzidine (DAB, D5905, Sigma) þ
1930.015% H2O2 (107209, Merck Millipore) in the dark. Nuclei
194were stained with Mayer's hematoxylin, and tissues were dehy-
195drated in propanol, dipped in xylene, and mounted. Positive
196controls consisted of PDGFR-expressing ovarian carcinoma,
197PTEN-expressing normal endometrium, ERBB2-expressing breast
198carcinoma, EGFR-expressing tumor (grown in nude mice) from
199human HEC cells and S6-expressing endometrial carcinoma with
200S6 phosphorylation, conﬁrmed by Western blot analysis. To
201ensure no staining was caused by a speciﬁc binding of second-
202ary/tertiary molecules, control slides without addition of primary
203antibody were used.
204Evaluation and scoring of immunohistochemical stainings
205All stainings were evaluated semiquantitatively, using a scoring
206system (Supplementary Table S3) that takes into account both the
207staining intensity (0 ¼ absent, 1 ¼ weak, 2 ¼moderate, and 3 ¼
208strong) and the percentage of stained cells (0 ¼ absent, 1 ¼ less
209than 1%, 2 ¼ 1%–10%, 3 ¼ 11%–33%, 4 ¼ 34%–66%, and 5 ¼
21067%–100%; ref. 15). Both scores were added to obtain a maxi-
211mum score of 8. Stainings were evaluated only in the cellular
212component where expression was expected. Tissues were consid-
213ered positive at a cut-off score of 6, corresponding to strong
214positivity in11% of cells, moderate positivity in34% of cells,
215or weak staining in 67% of cells. This cutoff was deemed
216clinically relevant for therapeutic applications, as a targeted ther-
217apy would most likely be effective when a sufﬁcient number of
218cells express the target. For ERBB2, this coincides with the gen-
219erally applied scoring system approved by the FDA (16). Tissues
220were evaluated by the observer (T. Cuppens) and in randomly
221selected cases (25%) additionally by a second observer (A. Coose-
222mans). For these speciﬁc cases, a concordance of >90% was
223reached between scorings by the two independent researchers.
224Photographs of representative cases were taken using the Axios-
225kop microscope (MRc5, Zeiss) and the ZEN 2.0 software.
226Establishment and validation of PDX models
227Animal Q8experiments were approved by the Animal Ethics
228Committee of KU Leuven (Leuven, Belgium). Mouse xenograft
229models were established in collaboration with the Trace Platform
230(UZ/KU Leuven). Small fragments of tumor tissue (3-3-3 mm),
231obtained during necessary surgery or biopsy upon informed
232consent, were implanted interscapularly in female NMRI nude
233mice of minimum 6weeks old (Taconic) and expanded in several
234generations.
235Treatment of PDX models
236Mice were randomized according to tumor volume (when
237tumor volumes reached 200–250 mm3) and treated for 19 to
23822days (5–9mice/group for BEZ235- andplacebo-treatedgroups,
2393–7 mice for trabectedin-treated groups). Some mice in the
240trabectedin groups were excluded due to signs of toxicity around
241the tail vein. BEZ235 (Novartis, through Selleckchem, S1009)was
242prepared in 10%N-methyl-2-pyrrolidone (sc-237581, Santa Cruz
243Biotechnology)/90% polyethylene glycol (90878, Sigma) and
244administered orally, daily, in a dose of 40 mg/kg. Placebo-treated
245mice received the same volume of vehicle as the BEZ235-treated
246group. Trabectedin (Yondelis) was acquired from the UZ Leuven
247Hospital Pharmacy, aliquoted in DMSO (102952, Merck Milli-
248pore), and diluted in saline. It was administered intravenously
249(0.15 mg/kg; tail vein), once weekly. Tumor volumes were mea-
250sured with a caliper twice weekly (calculated using the following
Dual PI3K/mTOR Inhibition in Uterine Sarcoma
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253 formula: length width depth  p/6), and mice body weights
254 were monitored. Treatment was discontinued after 3 weeks or
255 when the tumor reached a volume of 2,000 mm3. After sacriﬁce,
256 all tumors were stained and scored for p-S6S240 level as before.
257 Signiﬁcant weight loss was deﬁned as a loss of 15% of the body
258 weight recorded at the beginning of the treatment.
259 Statistical analyses
260 IBM SPSS Statistics 20 was used for all statistical analyses
261 except for the in vivo treatment experiments. Age and tumor size
262 were considered continuous variables, whereas all other vari-
263 ables were categorical. The c2 test was used to compare staining
264 results (portion of positive samples) between histologic sub-
265 groups. To determine potential associations between stainings
266 and clinical variables (e.g., stage, age, tumor size) for primary
267 versus recurrent tumors and LG versus HG histologies, univar-
268 iate analyses were ﬁrst carried out using c2 tests for categorical
269 variables. Next, logistic regression was performed including
270 only one variable for continuous and categorical variables, to
271 permit direct comparison with multivariate logistic regression
272 analysis, including all variables that showed a signiﬁcant cor-
273 relation in univariate analysis. Univariate survival analyses
274 were carried out using the Kaplan–Meier method/log-rank test.
275 In the in vivo treatment experiments, tumor volumes of different
276 treatment groups were compared over time using two-way
277 repeated measures ANOVA in GraphPad.
278 Results
279 HG uterine sarcomas are characterized by aggressive clinical
280 behavior and poor prognosis
281 We collected and analyzed the following patient samples:
282 leiomyosarcoma (n ¼ 153), LGESS (n ¼ 68), UUS (n ¼ 26),
283 HGESS (n ¼ 13), STUMP (n ¼ 15), adenosarcoma (n ¼ 17), and
284 HG uSAR NOS (n ¼ 5), which could not be categorized in any
285 conventional tumor group. Leiomyosarcoma, HGESS, UUS, and
286 HG uSAR NOS are HG tumors. Of 17 adenosarcoma patients, 4
287 were diagnosed with an HG variant (with sarcomatous over-
288 growth). The remaining adenosarcoma were considered LG, as
289 well as the LGESS. No grade was assigned to STUMP cases. The
290 most important clinical data summarized per histologic subtype
291 are shown in Supplementary Table S1. Information on disease-
292 speciﬁc survival (DSS) and progression-free survival (PFS) was
293 available for 242 and 210 patients, respectively. First, we pooled
294 all patients with HG and LG tumors and compared their survival,
295 conﬁrming that HG tumors are clinically more aggressive (Sup-
296 plementary Fig. S1A and S1B, both P< 0.001). For LGpatients, the
297 5-year DSS and PFS rates were 86% and 64%, respectively,
298 whereas for HG patients, after 5 years only 33% were alive and
299 18% showed no progression. Next, we determined survival rates
300 for all separate subtypes (Supplementary Fig. S1C and S1D). The
301 5-year DSS rate was 0% to 22% in UUS patients, around 30% in
302 HGESS patients, and 35% in leiomyosarcoma patients, contrast-
303 ing with 85% in LGESS patients. Concurrently, the 5-year PFS rate
304 was 0% to 10% in UUS patients, 0% to 29% in HGESS patients,
305 18% in leiomyosarcoma patients, and 63% in LGESS patients. Of
306 note, patients diagnosed with STUMP had a signiﬁcantly better
307 PFS compared with patients diagnosed with leiomyosarcoma
308 (median PFS ¼ 41 months in STUMP and 17 months in leio-
309 myosarcoma, P¼ 0.023), although the difference in DSS was not
310 signiﬁcant (median DSS ¼ 52 months in STUMP and 35 months
312in leiomyosarcoma, P¼ 0.086), probably due to the low number
313of STUMP patients. For adenosarcoma patients, the 5-year sur-
314vival estimation was not feasible due to the smaller sample set,
315with fewer events. The 3 HG adenosarcoma patients with avail-
316able follow-up data died of disease within 26months (100%). Of
317the patients with LG adenosarcoma, only 1 of 11 (9%) patients
318died of disease (after 25months), and the follow-up time of other
319patients was between 19 and 119 months.
320Overall, patient subgroups with HG tumors are characterized
321by a substantially worse prognosis, and the largest subgroup of
322uterine sarcoma presented in our study, as in the general popu-
323lation, is leiomyosarcoma.
324The PI3K/mTOR pathway and PDGFR-a are potential targets in
325different uterine sarcoma subtypes
326On the basis of available literature data and therapeutic poten-
327tial (i.e., for which therapeutic agents are available and active in
328other cancer types), we investigated in our cohort of human
329uterine sarcoma samples the expression of the following drug-
330gable molecular targets: phospho-S6S240, PTEN, PDGFR-a,
331ERBB2, and EGFR. Their expression levels were determined in a
332total of 396 samples, including malignant tumors (leiomyosar-
333coma, LGESS, HGESS, UUS, adenosarcoma, and HG uSARNOS),
334tumors of uncertain malignancy (STUMP), benign tumors (leio-
335myoma and ESN), and normal myometrium and endometrium.
336Expression data for the ﬁve selected proteins are summarized
337in Table 1, per histologic subgroup, and for pooled HG and LG
338samples. Representative images for the stainings and a detailed
339description of the adopted scoring system are shown in Supple-
340mentary Fig. S2 and Supplementary Table S3, respectively. Tissues
341were consideredpositive at a score of 6orhigher, corresponding to
342weak staining in 67% of cells, moderate staining in 34% of
343cells, or strong staining in 10% of cells. Considering all uterine
344sarcomas and STUMP cases together, p-S6S240 was scored positive
345in 26% of samples. Loss of PTEN expression was seen in 34% of
346cases, with up to 50% loss in UUS samples. The most frequently
347expressed protein was PDGFR-a (82%), while ERBB2 and EGFR
348were detected in 5% and 9% of cases, respectively. EGFR was
349almost exclusively detected in the stromal component of adeno-
350sarcoma: 31% of LG adenosarcoma and 75% of HG adenosar-
351coma expressed EGFR. Remarkably, ERBB2 was mainly expressed
352in the epithelial component of adenosarcoma: 58% of LG ade-
353nosarcoma and 100% of HG adenosarcoma showed ERBB2
354expression. Although this component is considered benign, it
355showed more frequent ERBB2 expression compared with normal
356endometrial epithelial cells (P ¼ 0.001 for LG and P < 0.001 for
357HG, as determined by c2 test).
358Taken together, our data show that PDGFR-a is a potential
359target in all uterine sarcoma subtypes, PI3K/mTOR targeting is an
360option in 26% of cases, mainly leiomyosarcoma, HGESS and
361UUS, and ERBB2/EGFR seem to be targetable in a minority of
362cases, mostly adenosarcoma. Recently, pazopanib, a multikinase
363inhibitor also targeting PDGFR, was approved for treatment of
364leiomyosarcoma after a successful randomized phase III trial (the
365PALETTE study; ref. 17), conﬁrming the potential predictive value
366of such a histologic scoring system.
367In addition, we assessed cyclin D1 expression and the presence
368of t(10;17)(q22;p13) rearrangement, leading to the fusion gene
369YMHAE/NUTM2A/B, in HGESS and UUS cases because these
370alterations have been linked to HGESS and as the 14-3-3 onco-
371protein, resulting from the translocation, has been suggested as a
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374 therapeutic target (18–20). We conﬁrmed that cyclin D1 was
375 expressed more in HGESS (7/15; 47%) than in UUS (4/25;
376 16%), as shown by the c2 test (P ¼ 0.035). Likewise, previous
377 studies have reported 8 of 14 and 7of 18 cyclin D1–positive
378 HGESS cases (18, 21). Of 12 interpretable HGESS and 19 UUS
379 cases, only 2HGESS cases showed the t(10;17) translocation (one
380 was conﬁrmed by RT-PCR; the other case had no available RNA)
381 and both had very strong (>90% positive nuclei) cyclin D1
382 staining, conﬁrming the ﬁndings by Lee and colleagues (ref. 22;
383 see Supplementary Methods and Supplementary Fig. S3). Our
384 results are in line with previous studies that detected the translo-
385 cation with FISH, where 4 of 14 and 4 of 16 cases were positive
386 (18, 21). Although the portion of translocation-positive cases is
387 higher in other studies (7/12 and 5/8), this may be explained by
388 variability between methods, as exempliﬁed by Micci and collea-
389 gues (20, 23). Cyclin D1 expression did not correlate with DSS,
390 PFS, or any of the ﬁve investigated proteins.
391 P-S6S240 expression correlates with recurrent and HG tumors
392 and with shorter PFS
393 To identify links between protein expression and tumor char-
394 acteristics, we checked for correlations with tumor grade and
395 primary versus recurrent tumors. Remarkably, p-S6S240 was
396 observed more frequently in HG tumors (66/205; 32%) than in
397 LG tumors (7/79; 9%; P ¼ 0.004) and was also detected more
398 frequently in recurrent tumors (15/36; 42%) than in primary
399 tumors (60/261; 23%; P ¼ 0.016), as calculated by c2 test. Also,
400 ERBB2 was expressed more frequently in recurrent tumors (5/37;
401 14%) than in primary tumors (9/264; 3%; P ¼ 0.006). Subse-
402 quently, logistic regression analyses (correcting for other factors
403 correlated with grade and recurrence) showed that p-S6S240 was
404 independently associated with both histologic aggressiveness
405 (P¼ 0.001; Table 2) and recurrence (P¼ 0.019; Table 3), whereas
406 ERBB2was associated onlywith recurrence (P¼ 0.011). Together,
407 these ﬁndings suggest that mTOR pathway activation may be
408 associated with disease progression in uterine sarcomas. Because
409 leiomyosarcomas represent the largest uterine sarcoma subgroup,
410 and are generally HG, we further focused our analyses on this
411 subgroup. In leiomyosarcoma, phosphorylation of S6S240 was
412 detected in 29%of cases, signiﬁcantlymore frequently than in LM
414(P < 0.001; c2 test) and healthy myometrium (P ¼ 0.018).
415P-S6S240 was the only variable that was more often detected in
416recurrent leiomyosarcoma (11/22; 50%) than in primary leio-
417myosarcoma (32/131; 24%; P ¼ 0.014; c2 test); hence, multivar-
418iate analysis was irrelevant. Of note, two primary metastatic
419leiomyosarcomas were included in the analysis and both showed
420p-S6S240 positivity. To assess the potential prognostic value of the
421investigated proteins, we carried out survival analyses in uterine
422sarcoma subgroups. Interestingly, p-S6S240 positivity correlated
423with shorter PFS in leiomyosarcoma patients (P ¼ 0.034) and
424showed a trend toward shorter DSS in univariate analysis (Fig. 1A
425and B). Loss of PTEN, which negatively regulates PI3K signaling,
426correlated with shorter DSS (P ¼ 0.039) in leiomyosarcoma
427patients, but not with PFS (Fig. 1C and D). Multivariate analysis
428was not feasible due to the small sample size obtained after
429ﬁltering out cases with missing data.
430Taken together, our data suggest that p-S6S240 correlates with
431HG and recurrent uterine sarcomas, an observation that was also
432conﬁrmed in leiomyosarcoma cases, the largest uterine sarcoma
433subgroup. In addition, p-S6 and PTENmay have prognostic value
434in leiomyosarcoma patients.
435Dual inhibition of mTOR and PI3K reduces tumor growth
436in p-S6S240–positive leiomyosarcoma PDX models
437The ﬁnding that p-S6S240 positivity is correlated with HG and
438recurrent uterine sarcomas suggests that mTOR pathway activa-
439tion may play a central role in uterine sarcoma progression. To
440validate this observation, we decided to test the efﬁcacy of mTOR
441pathway inhibition in clinically relevant PDX models of uterine
442leiomyosarcoma. Despite previous clinical trials with mTOR-
443targeting agents for treatment of leiomyosarcoma patients, so far,
444noneof the tested compounds (e.g., ridaforolimus, temsirolimus)
445have been approved for leiomyosarcoma by the FDA (7). It has
446been suggested that the lack of clinical effect could be due to the
447feedback activation of AKT as a consequence of mTOR complex 1
448(mTORC1) inhibition, which can sustain tumor growth through
449mTOR complex 2 (mTORC2) signaling (24, 25). For this reason,
450we selected a dual PI3K/mTOR inhibitor, BEZ235, also able to
451block mTORC2. Five PDX models were derived from uterine
452leiomyosarcoma of different patients, from which the clinical
Table 2. LogisticQ10 regression: predictors of HG versus LG histology
VariableQ11 N Univariate OR (95% CI) P Multivariate OR (95% CI) P
p-S6S240
Negative 120 1
Positive 44 5.385 (1.803–16.082) 0.003 7.242 (2.294–22.866) 0.001
Tumor size 164 1.176 (1.076–1.286) <0.001 1.158 (1.056–1.270) 0.002
Age 164 1.034 (1.008–1.061) 0.010 1.027 (0.998–1.057) 0.064
NOTE: Logistic regression with "LG histology" as a reference. OR > 1 and P < 0.05 indicate a statistically signiﬁcant correlation of the variable with HG histology.
Abbreviation: CI, conﬁdence interval.
Table 3. LogisticQ12 regression: predictors of recurrent versus primary tumor samples
Variable N Univariate OR (95% CI) P Multivariate OR (95% CI) P
p-S6S240
Negative 222 1
Positive 75 2.393 (1.162–4.929) 0.018 2.408 (1.156–5.016) 0.019
ERBB2
Negative 283 1
Positive 14 4.516 (1.423–14.336) 0.011 4.567 (1.406–14.827) 0.011
NOTE: Logistic regressionwith "primary tumors" as a reference. OR > 1 andP < 0.05 indicate a statistically signiﬁcant correlation of the variablewith recurrent samples.
Abbreviation: CI, conﬁdence interval.
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455 characteristics are shown in Supplementary Table S4. Eachmodel
456 was treated for 3 weeks with BEZ235, placebo, and trabectedin
457 (Yondelis), an alkylating chemotherapeutic agent approved for
458 leiomyosarcoma treatment after failure of anthracyclines. We
459 chose trabectedin as a chemotherapy control as it is the youngest,
460 most recently approved chemotherapy. Its antiproliferative prop-
461 erties rely on multiple mechanisms, including the inhibition of
462 transactivated transcription and the interaction with DNA repair
463 proteins (26). Of ﬁve treated leiomyosarcoma models, four
464 showed response to dual PI3K/mTOR inhibition (Fig. 2).Whereas
465 the tumor volume was stabilized in EMC029, tumor growth was
466 slowed down in EMC050. Furthermore, tumor shrinkage was
467 observed in EMC036 (21% reduction, compared with placebo)
468 and EMC041 (35% reduction, compared with placebo). No
469 response to BEZ235was noted in EMC031, a recurrent, pretreated
470 leiomyosarcoma. Response to trabectedin was noted in four
471 models, while EMC029 showed a trend (nonsigniﬁcant) toward
473response after 8 days. No mice in any arms of the treatment
474experiments showed signiﬁcant weight loss (data not shown).
475Interestingly, the four responding models showed in their
476placebo-treated tumors expression of p-S6S240, with mean scores
477between 6,3 and 7,8 (see Table 4 for mean scores; representative
478images are shown in Fig. 2), whereas all BEZ235-treated tumors
479were scored as negative. In the nonresponding model (EMC031),
480p-S6S240 staining in placebo-treated tumors was scored as nega-
481tive, with amean score of 5,1. These ﬁndings suggest that p-S6S240
482expression can be used to predict response to PI3K/mTOR block-
483age in leiomyosarcoma.
484To extend our testing of dual PI3K/mTOR inhibition beyond
485BEZ235, EMC041was additionally treated with a combination of
486the mTORC1/2 inhibitor TAK-228 and the PI3Ka inhibitor alpe-
487lisib. The combinationof TAK-228 andalpelisibwas as effective as
488BEZ235 in inhibiting tumor growth (no signiﬁcant difference
489between both treatment groups), supporting in general our
Figure 1.
Survival of leiomyosarcoma patients according to p-S6S240 and PTEN expression. A–D, Kaplan–Meier survival curves showing DSS (A and C) and PFS (B and D)
of leiomyosarcoma patients. A and B, The log-rank test with corresponding P values applies to the p-S6S240–negative (red) and p-S6S240–positive (green)
curves. Blue curves (all leiomyosarcomas) are depicted as comparison. The number of patients in the analyses is indicated next to the curve with number of
events between brackets. C and D, The log-rank test applies to the PTEN-negative (red) and PTEN-positive (green) curvesQ13 .
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Figure 2.
In vivo dual inhibition of mTOR and PI3K by BEZ235 in uterine leiomyosarcoma PDX models. Mice were treated with BEZ235, trabectedin (as a chemotherapy
control), or placebo. Tumor volumes were measured twice weekly, and growth curves of treated mice were compared with placebo-treated mice using
two-way repeated measures ANOVA. Data points and error bars represent mean values and SEM. Signiﬁcant effects (compared with placebo) are indicated with
 and  . Tumor growth curves are depicted with p-S6S240 stainings and scores of representative tumors of each model (left, placebo-treated tumor; right,
BEZ235-treated tumor). Pictureswere taken at20magniﬁcation (scale bar, 50mm)andat40magniﬁcation for EMC029 (scale bar, 20mm). A largermagniﬁcation
was used for EMC029 to increase visibility as the cells show a small amount of cytoplasm. Numbers of mice for placebo, trabectedin, and BEZ235-treated
groups are respectively: EMC036: n ¼ 6, 6, 5; EMC050: n ¼ 6, 7, 6; EMC041: n ¼ 6, 3, 6; EMC029: n ¼ 5, 4, 5; EMC031: 7, 7, 9.
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492 approach of dual PI3K/mTOR inhibition in leiomyosarcoma
493 (Supplementary Methods; Supplementary Fig. S4).
494 Thus, four of ﬁve uterine leiomyosarcoma models, which were
495 p-S6S240 positive, responded to dual PI3K/mTOR inhibition,
496 which can represent anew therapeutic option for leiomyosarcoma
497 patients with p-S6S240–positive tumors.
498 Discussion
499 We analyzed a large cohort of samples from uterine sarcoma
500 patients for the expression of selected druggable therapeutic
501 targets, to determine the subgroups for which speciﬁc targeted
502 agents would be the most potentially effective.
503 Here, we show that PDGFR-a is expressed in the majority of
504 samples, in all sarcoma subtypes. Importantly, after initiation of
505 this study, pazopanib, targeting PDGFR, KIT, FGFR, and VEGFR,
506 was approved for the treatment of leiomyosarcomapatients after a
507 successful placebo-controlled phase III trial (17). Another recent
508 phase II trial showed the addition of PDGFR-a inhibitor olar-
509 atumab todoxorubicin is beneﬁcial in soft tissue sarcomapatients
510 (including leiomyosarcoma; ref. 27). Our results conﬁrm that
511 PDGFR-a is frequently expressed in uterine leiomyosarcoma, but
512 also other uterine sarcoma types show expression in at least 75%
513 of cases, suggesting that pazopanib/olaratumab should also be
514 tested in other uterine sarcoma subtypes. Of note, 2 LGESS
515 patients have been reported to show response to imatinib in case
516 reports, encouraging further studies (28, 29). Although one case
517 expressed KIT (PDGFR status unknown), the other case showed
518 no KIT expression or activating mutation, but was strongly pos-
519 itive for PDGFR, suggesting imatinib acted through PDGFR in the
520 latter case. Indeed, because KIT is notmutated in uterine sarcomas
521 (6), imatinib may exert its effect by PDGFR blocking in uterine
522 sarcomas (9).
523 ERBB2 and EGFR, although being important targets in other
524 cancer types, havenot been studied frequently in uterine sarcomas
525 (7). An exception is the study by Movva and colleagues (6),
526 describing that ERBB2 is rarely overexpressed in leiomyosarcoma
527 and ESS. In our sample set, ERBB2 and EGFRwere rarely detected,
528 except in adenosarcoma. ERBB2 was expressed in the epithelial
529 component in 58% of LG adenosarcoma and in 100% of HG
530 adenosarcoma cases. Contrarily, EGFR expression in adenosar-
531 coma was seen in a minority of epithelial cells, whereas it was
532 expressed in the stromal component in 31% of LG adenosarcoma
533 and in 75% of HG adenosarcoma cases. This stromal–epithelial
534 distribution of EGFR and ERBB2 in adenosarcoma is in line with
535 their expression pattern in carcinosarcomas (30–32). Only two
536 other studies reported on the expression of EGFR (2/6 positive
537 cases) and ERBB2 (0/6 and 0/10 positive cases) in adenosarcoma,
538 but without evaluating the epithelial component (30, 32). In
539 addition, we show that in uterine sarcomas, ERBB2 is more
541frequently detected in recurrent samples than in primary tumors,
542suggesting that ERBB2 may play a role in sarcoma progression.
543The PI3K/mTOR pathway has been implicated in the patho-
544genesis of leiomyosarcoma, and preclinical studies have shown
545effect of mTOR-targeting agents (7, 8). A negative regulator of
546PI3K/mTOR signaling, PTEN, is frequently deleted in leiomyo-
547sarcoma (6, 33). In our cohort, absence or low expression of PTEN
548was noted in 28%of leiomyosarcoma samples. This is concordant
549with earlier ﬁndings, showing decreased expression of PTEN in
55020% to 38% of leiomyosarcoma cases (6, 34). Another study
551reported PTEN loss by IHC in only 7%of uterine leiomyosarcoma
552(35). This discrepancy is likely due to the use of different
553scoring systems. In leiomyosarcoma patients, we showed that
554PTEN loss correlates with shorter DSS. PTEN loss has been
555shown previously to have prognostic value in other gynecologic
556cancer types (36, 37). Next to its prognostic role, loss of PTEN
557may also guide therapy decisions. Indeed, PTEN-deﬁcient
558tumors may be more sensitive to PARP inhibitors, due to
559PTEN's role in genomic integrity, with PTEN loss leading to
560defects in homologous recombination (38).
561Downstream tomTOR signaling, S6 kinases (S6K) are activated
562through phosphorylation. A well-known target of S6K is the S6
563ribosomal protein, a component of the 40S ribosomal protein.
564Here,we used the phosphorylated formof S6 as a read-out for S6K
565activity, and thus mTOR pathway activation (39). The S6 protein
566can be phosphorylated at serines 235/236 and 240/244. Pende
567and colleagues (40) have described phosphorylation at S235/236
568even when mTOR-activated kinases S6K1 and 2 are knocked out.
569In this situation, phosphorylation at S240/244 was obliterated,
570suggesting that mTOR-activated S6K1/2s are the only kinases
571responsible for phosphorylation at serines 240/244 in the S6
572protein (40). Therefore, we chose to detect S6 phosphorylation at
573serine 240 using a phospho-site–speciﬁc antibody. In our dataset,
57429% of uterine leiomyosarcoma samples showed p-S6S240 pos-
575itivity, signiﬁcantly more than in benign lesions and normal
576tissue. Similarly, Brewer Savannah and colleagues (35) reported
57724% of uterine leiomyosarcoma to be strongly positive, and
578Hernando and colleagues (41) found 44% of soft tissue leiomyo-
579sarcoma samples to be p-S6S240 positive. Setsu and colleagues
580(34) found 74,5% of soft tissue leiomyosarcoma samples to be
581p-S6S235/236 positive. However, the latter report did not include
582uterine lesions and used a lower cutoff for positivity.
583In our study, p-S6S240 staining was observed more in HG and
584recurrent tumors, suggesting that S6 phosphorylationmight be an
585event linked to disease progression. This ﬁnding is in line with the
586previous report of Brewer Savannah and colleagues (35), who
587observed higher levels of p-S6S235/236 in recurrent and metastatic
588uterine leiomyosarcoma lesions. We are the ﬁrst to report this
589ﬁnding in a large cohort of 153 uterine leiomyosarcoma patients.
590Furthermore, we show that p-S6S240 positivity correlates with
Table 4. Response of PDX models to BEZ235 with p-S6S240 scores
Model Response to BEZ235
p-S6S240 mean score
placebo-treated tumors
p-S6S240 status placebo-
treated tumors
EMC036 Decrease in tumor volume 7,8 Positive
EMC050 Decrease in tumor growth 7,7 Positive
EMC041 Decrease in tumor volume 7,0 Positive
EMC029 Stable tumor volume 6,3 Positive
EMC031 No response 5,1 Negative
NOTE: Five PDX models were treated with BEZ235, trabectedin, and placebo. Placebo-treated tumors were scored for p-S6S240 level. For each model, the mean
scores of all placebo-treated tumors are depicted.
Dual PI3K/mTOR Inhibition in Uterine Sarcoma
www.aacrjournals.org Clin Cancer Res; 23(5) March 1, 2017 9
593 shorter PFS in leiomyosarcoma patients; hence, p-S6S240 could be
594 a prognostic marker in leiomyosarcoma patients.
595 MTOR inhibition showed modest effectiveness in preclinical
596 studies and in clinical trials on sarcomas, where leiomyosarcoma
597 patients (origin not speciﬁed) showed minor response to ridafor-
598 olimus and temsirolimus (7, 42, 43). Taking into account their
599 limited clinical effect, as well as the toxicities, the FDA has not
600 approved mTOR inhibitors for leiomyosarcoma patients so far.
601 This limited efﬁcacy may be partly due to the absence of patient
602 selection, as no predictive markers are currently available. In
603 addition, these compounds only inhibit mTORC1, which may
604 lead to feedback activation of AKT and sustained signaling
605 through mTORC2 (25). New-generation inhibitors targeting also
606 mTORC2, as well as PI3K, have not been tested in gynecologic
607 sarcomas until very recently. SK-LMS-1, a vulvar leiomyosarcoma
608 cell line, has proven to be sensitive to BEZ235, the same dual
609 PI3K/mTOR inhibitor that we tested in our study (44). BEZ235
610 has also been shown to inhibit the proliferation of pazopanib-
611 resistant retroperitoneal undifferentiated pleomorphic sarcoma
612 (UPS) cells (45). However, in a genetically engineered mouse
613 model ofUPS, BEZ235 inhibited tumor growth inonly 3of 9mice
614 (46). BEZ235 inhibits various sarcoma cell lines, including rhab-
615 domyosarcoma, Ewing sarcoma, osteosarcoma, and chondrosar-
616 coma cells in vitro, although reported in vivomodels show varying
617 response (47, 48).
618 In contrast with the cell line–based in vivo models, which
619 have been used in most studies on sarcomas, we have chosen to
620 establish PDX models, which better represent the original
621 tumor characteristics (13). Here, we show a strong response
622 of uterine leiomyosarcoma PDX models to BEZ235. Unfortu-
623 nately, after initiation of this study, BEZ235 development was
624 discontinued by Novartis, mainly due to toxicity (49).
625 BEZ2350s clinical toxicity proﬁle was unexpected because no
626 such adverse effects were observed in our preclinical tests or in
627 previous preclinical studies (47, 48). However, our results
628 provide preclinical evidence for the efﬁcacy of dual PI3K/mTOR
629 inhibition in uterine leiomyosarcoma patients, supporting the
630 use of other (less toxic) dual PI3K/mTOR inhibitors like geda-
631 tolisib (Pﬁzer), as well as combinations of PI3K inhibitors (e.g.,
632 alpelisib by Novartis) and mTOR inhibitors (e.g., TAK-228 by
633 Takeda). Indeed, we here show that combined administration
634 of mTORC1/2 inhibitor TAK-228 and PI3Ka inhibitor alpelisib
635 results in an equal tumor inhibition as obtained by BEZ235,
636 supporting our approach of dual PI3K/mTOR targeting in
637 leiomyosarcoma. Intriguingly, models showing p-S6S240
638 expression responded better to PI3K/mTOR targeting, suggest-
639 ing that p-S6S240 could be used as a predictive marker for
640 response to PI3K/mTOR–directed agents. Iwenofu and collea-
641 gues (50) have previously suggested a role for p-S6S235/236 in
642 response prediction to ridaforolimus in sarcoma patients;
643 however, no uterine sarcomas were included in their study
644 (50). Taken together, our ﬁndings suggest that dual PI3K/
645 mTOR targeting might be an effective strategy in uterine
646 leiomyosarcoma.
648In conclusion, the expression of ﬁve therapeutically relevant
649proteins was assessed in all uterine sarcoma subtypes, as well as in
650benign uterine tumors and normal tissues. In a set of 303 uterine
651sarcomas, we show that p-S6S240 expression identiﬁes sarcomas
652with a poor prognosis and predicts response to dual PI3K/mTOR
653inhibition in PDX leiomyosarcoma models.
654Disclosure of Potential Conﬂicts of Interest
655Eva Wardelmann has received speakers bureau honoraria from Bayer,
656Menarini, Nanobiotis, andNovartis and is a consultant/advisory boardmember
657for MSD, New Oncology, and Novartis. No potential conﬂicts of interest were
658disclosed Q14by the other authors.
659Authors' Contributions
660Conception and design: T. Cuppens, K. Van de Vijver, H.B. Salvesen, F. Amant
661Development of methodology: T. Cuppens, N. ter Haar, G. Verbist, T. Bosse,
662F. Amant
663Acquisition of data (provided animals, acquired and managed patients,
664provided facilities, etc.): T. Cuppens, A. Coosemans, J. Trovik, N. ter Haar,
665E. Colas, A. Garcia-Jimenez, K. Van de Vijver, R.P.M. Kruitwagen, Mari€el
666Brinkhuis, M. Zikan, P. Dundr, J. Huvila, O. Carpen, J. Haybaeck, F. Moinfar,
667H.B. Salvesen, M. Stukan, C. Mestdagh, R.P. Zweemer, L.F. Massuger,
668M.R. Mallmann, E. Wardelmann, M. Mints, G. Verbist, D. Thomas, E. Hermans,
669P. Moerman, T. Bosse, F. Amant
670Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
671computational analysis): T. Cuppens, J. Trovik, N. ter Haar, P. Dundr,
672O. Carpen, J. Haybaeck, F. Moinfar, F. Amant
673Writing, review, and/or revision of the manuscript: T. Cuppens, D. Annibali,
674A. Coosemans, J. Trovik, N. ter Haar, E. Colas, K. Van de Vijver, R.P.M.
675Kruitwagen, Mari€el Brinkhuis, M. Zikan, P. Dundr, J. Huvila, O. Carpen,
676J. Haybaeck, F. Moinfar, M. Stukan, R.P. Zweemer, L.F. Massuger, M.R. Mal-
677lmann, E. Wardelmann, M. Mints, D. Thomas, P. Moerman, T. Bosse, F. Amant
678Administrative, technical, or material support (i.e., reporting or organizing
679data, constructing databases): T. Cuppens, M. Zikan, J. Haybaeck, M.R. Mal-
680lmann, E. Wardelmann, E. Gomme, E. Hermans, T. Bosse, F. Amant
681Study supervision: Q15T. Cuppens, K. Van de Vijver, T. Bosse, F. Amant
682Other (minor revision): J. Huvila
683Acknowledgments
684The authors would like to thank Trudy Jonges, Rene Verheijen, and Louis van
685der Putten for selecting and retrieving tumor specimens and clinical data, Britt
686Edvardsen for assistance in retrieving tumor specimens, Ellen Valen for retriev-
687ing clinical data, Urszula S´miaøek for preparing tumor samples, and Jeroen
688Depreeuw and Stijn Moens for helping with treatment experiments.
689Grant Support Q16
690T. Cuppens and A. Coosemans were supported by FWO with a PhD
691(11M9814/16N) and a postdoctoral (12F3114N) fellowship, respectively.
692Prague's collection was supported by biobanking grant project LM 2015089.
693Stockholm's collection was supported by Swedish Labor Market Insurance and
694Swedish Medical Research Council (number 20110222). Norway's collection
695was supported by Helse-Vest, The Norwegian Cancer Society, and The Norwe-
696gian Research Council.
697The costs of publication of this articlewere defrayed inpart by the payment of
698page charges. This article must therefore be hereby marked advertisement in
699accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
700Received August 26, 2016; revised November 3, 2016; accepted November 8,
7012016; published OnlineFirst xx xx, xxxx.
702 References
703 1. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen
704 GB. Uterine sarcomas in Norway. A histopathological and prognostic
705 survey of a total population from 1970 to 2000 including 419 patients.
706 Histopathology 2009;54:355–64.
7082. Amant F,CoosemansA,Debiec-RychterM,TimmermanD,Vergote I.Clinical
709management of uterine sarcomas. Lancet Oncol 2009;10:1188–98.
7103. Peeters N, Hulsbosch S, Ballaux F, Baekelandt J. Uterine smooth muscle
711tumors of uncertain malignant potential: analysis of diagnoses and
Cuppens et al.
Clin Cancer Res; 23(5) March 1, 2017 Clinical Cancer Research10
714 therapies illustrated by two case reports. Eur J Gynaecol Oncol
715 2016;37:367–73.
716 4. Novetsky AP, Powell MA. Management of sarcomas of the uterus. Curr
717 Opin Oncol 2013;25:546–52.
718 5. GuoX, Jo VY,Mills AM, Zhu SX, LeeCH, Espinosa I, et al. Clinically relevant
719 molecular subtypes in leiomyosarcoma. Clin Cancer Res 2015;21:
720 3501–11.
721 6. Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, et al. Multi-
722 platform proﬁling of over 2000 sarcomas: identiﬁcation of biomarkers and
723 novel therapeutic targets. Oncotarget 2015;6:12234–47.
724 7. Cuppens T, Tuyaerts S, Amant F. Potential therapeutic targets in uterine
725 sarcomas. Sarcoma 2015;2015:243298.
726 8. Wong TF, Takeda T, Li B, Tsuiji K, Kondo A, Tadakawa M, et al. Curcumin
727 targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth
728 suppression. Int J Clin Oncol 2014;19:354–63.
729 9. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment.
730 Cell Commun Signal 2013;11:97.
731 10. Fabi A, Malaguti P, Vari S, Cognetti F. First-line therapy in HER2 positive
732 metastatic breast cancer: is the mosaic fully completed or are we missing
733 additional pieces? J Exp Clin Cancer Res 2016;35:104.
734 11. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor
735 receptor targeting in cancer: a review of trends and strategies. Biomaterials
736 2013;34:8690–707.
737 12. Daniel VC,Marchionni L,Hierman JS, Rhodes JT,DevereuxWL, RudinCM,
738 et al. A primary xenograft model of small-cell lung cancer reveals irrevers-
739 ible changes in gene expression imposed by culture in vitro. Cancer Res
740 2009;69:3364–73.
741 13. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al.
742 Patient-derived xenograft models: an emerging platform for translational
743 cancer research. Cancer Discov 2014;4:998–1013.
744 14. Oliva E, Carcangiu ML, Carinelli SG, Ip P, Loening T, Longacre TA, et al.
745 Tumours of the uterine corpus—mesenchymal tumours. In: Kurman RJ,
746 editor. WHO classiﬁcation of tumours of female reproductive organs.
747 Lyon, France: International Agency for Research on Cancer; 2014.
748 p. 135–47.
749 15. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, et al.
750 Immunohistochemical detection of steroid receptors in breast cancer: a
751 working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast
752 Cancer PathologyGroup, and The Receptor and Biomarker StudyGroup of
753 the EORTC. J Clin Pathol 2000;53:634–5.
754 16. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Speciﬁcity of
755 HercepTest in determining HER-2/neu status of breast cancers using the
756 United States Food and Drug Administration-approved scoring system.
757 J Clin Oncol 1999;17:1983–7.
758 17. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG,
759 et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a rando-
760 mised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:
761 1879–86.
762 18. Croce S,Hostein I, Ribeiro A, GarbayD, Velasco V, Stoeckle E, et al. YWHAE
763 rearrangement identiﬁed by FISH and RT-PCR in endometrial stromal
764 sarcomas: genetic and pathological correlations. Mod Pathol 2013;26:
765 1390–400.
766 19. Kurihara S, Oda Y, Ohishi Y, Kaneki E, Kobayashi H, Wake N, et al.
767 Coincident expression of beta-catenin and cyclin D1 in endometrial
768 stromal tumors and related high-grade sarcomas. Mod Pathol 2010;23:
769 225–34.
770 20. LeeCH,OuWB,Marino-EnriquezA, ZhuM,MayedaM,WangY, et al. 14-3-
771 3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl
772 Acad Sci U S A 2012;109:929–34.
773 21. Sciallis AP, Bedroske PP, Schoolmeester JK, Sukov WR, Keeney GL, Hodge
774 JC, et al. High-grade endometrial stromal sarcomas: a clinicopathologic
775 study of a group of tumors with heterogenous morphologic and genetic
776 features. Am J Surg Pathol 2014;38:1161–72.
777 22. Lee CH, Ali RH, RouzbahmanM, Marino-Enriquez A, ZhuM, Guo X, et al.
778 CyclinD1as adiagnostic immunomarker for endometrial stromal sarcoma
779 with YWHAE-FAM22 rearrangement. Am J Surg Pathol 2012;36:1562–70.
780 23. Micci F, Gorunova L, Agostini A, Johannessen LE, Brunetti M, Davidson B,
781 et al. Cytogenetic and molecular proﬁle of endometrial stromal sarcoma.
782 Genes Chromosomes Cancer 2016;55:834–46.
783 24. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, et al.
784 Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad
786antitumor activity and can be optimally administered using intermittent
787dosing regimens. Mol Cancer Ther 2011;10:1059–71.
78825. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces
789feedback activation of Akt signaling through an IGF-1R-dependent mech-
790anism. Oncogene 2007;26:1932–40.
79126. Larsen AK, Galmarini CM, D'Incalci M. Unique features of trabectedin
792mechanism of action. Cancer Chemother Pharmacol 2016;77:663–71.
79327. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al.
794Olaratumab and doxorubicin versus doxorubicin alone for treatment of
795soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
796Lancet 2016;388:488–97.
79728. Kalender ME, Sevinc A, Yilmaz M, Ozsarac C, Camci C. Detection of
798complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG
799PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother
800Pharmacol 2009;63:555–9.
80129. Trojan A, Montemurro M, Kamel M, Kristiansen G. Successful PDGFR-
802{alpha}/{beta} targeting with imatinib in uterine sarcoma. Ann Oncol
8032009;20:1898–9.
80430. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L,
805MoermanP, et al. ERBB-2 gene overexpression and ampliﬁcation in uterine
806sarcomas. Gynecol Oncol 2004;95:583–7.
80731. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expres-
808sion and HER2/neu overexpression/ampliﬁcation in endometrial carcino-
809sarcoma. Gynecol Oncol 2006;100:101–6.
81032. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, et al. The
811expression of epidermal growth factor receptor, HER-2/Neu, p53, and
812Ki-67 antigen in uterine malignant mixed mesodermal tumors and ade-
813nosarcoma. Gynecol Oncol 1996;60:81–8.
81433. Raish M, Khurshid M, Ansari MA, Chaturvedi PK, Bae SM, Kim JH, et al.
815Analysis ofmolecular cytogenetic alterations in uterine leiomyosarcomaby
816array-based comparative genomic hybridization. J Cancer Res Clin Oncol
8172012;138:1173–86.
81834. Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, et al.
819The Akt/mammalian target of rapamycin pathway is activated and asso-
820ciated with adverse prognosis in soft tissue leiomyosarcomas. Cancer
8212012;118:1637–48 Q17.
82235. Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R,
823Young E, et al. Dual targeting of mTOR and aurora-A kinase for the
824treatment of uterine Leiomyosarcoma. Clin Cancer Res 2012;18:4633–45.
82536. Martins FC, Santiago I, Trinh A, Xian J, Guo A, Sayal K, et al. Combined
826image and genomic analysis of high-grade serous ovarian cancer reveals
827PTEN loss as a commondriver event andprognostic classiﬁer. GenomeBiol
8282014;15:526.
82937. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by
830Akt phosphorylation is a poor prognostic factor for patients with endo-
831metrial cancer. Endocr Relat Cancer 2003;10:203–8.
83238. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS,
833et al. Synthetic lethal targeting of PTENmutant cells with PARP inhibitors.
834EMBO Mol Med 2009;1:315–22.
83539. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev
8362004;18:1926–45.
83740. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al.
838S6K1(/)/S6K2(/) mice exhibit perinatal lethality and rapamycin-
839sensitive 50-terminal oligopyrimidine mRNA translation and reveal a
840mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell
841Biol 2004;24:3112–24.
84241. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I,
843Mills J, et al. The AKT-mTOR pathway plays a critical role in the develop-
844ment of leiomyosarcomas. Nat Med 2007;13:748–53.
84542. Demetri GD, Chawla SP, Ray-Coquard I, Le CA, Staddon AP, MilhemMM,
846et al. Results of an international randomized phase III trial of the mam-
847malian target of rapamycin inhibitor ridaforolimus versus placebo to
848control metastatic sarcomas in patients after beneﬁt from prior chemo-
849therapy. J Clin Oncol 2013;31:2485–92.
85043. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, et al. A
851phase 2 study of temsirolimus (CCI-779) in patients with soft tissue
852sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer
8532011;117:3468–75.
85444. Babichev Y, Kabaroff L, Datti A, Uehling D, Isaac M, Al-Awar R, et al. PI3K/
855AKT/mTOR inhibition in combination with doxorubicin is an effective
856therapy for leiomyosarcoma. J Transl Med 2016;14:67.
Dual PI3K/mTOR Inhibition in Uterine Sarcoma
www.aacrjournals.org Clin Cancer Res; 23(5) March 1, 2017 11
859 45. KimHK, Kim SY, Lee SJ, KangM, Kim ST, Jang J, et al. BEZ235 (PIK3/mTOR
860 inhibitor) overcomes pazopanib resistance in patient-derived refractory
861 soft tissue sarcoma cells. Transl Oncol 2016;9:197–202.
862 46. Kim S, Dodd RD, Mito JK, Ma Y, Kim Y, Riedel RF, et al. Efﬁcacy of
863 phosphatidylinositol-3 kinase inhibitors in a primary mouse model of
864 undifferentiated pleomorphic sarcoma. Sarcoma 2012;2012:680708.
865 47. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L,
866 et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer
867 Res 2010;16:530–40.
868 48. Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van WT,
869 et al. Functional proﬁling of receptor tyrosine kinases and downstream
871signaling in human chondrosarcomas identiﬁes pathways for rational
872targeted therapy. Clin Cancer Res 2013;19:3796–807.
87349. Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J, et al. A
874phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol
8753-Kinase (PI3K) and mammalian target of rapamycin (mTOR), in
876patients with advanced renal cell carcinoma. Oncologist 2016;21:
877787–8.
87850. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM,
879Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive
880sarcoma marker for targeted mTOR therapy. Mod Pathol 2008;21:
881231–7.
Clin Cancer Res; 23(5) March 1, 2017 Clinical Cancer Research12
Cuppens et al.
